Now FDA Approved
For adults with relapsed or refractory multiple myeloma
ELREXFIO is a prescription medication used to treat adults with multiple myeloma who:
- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and
- their cancer has come back or did not respond to prior treatment
ELREXFIO was approved based on patient responses and durability of response. There are ongoing studies to confirm its clinical benefit. It is not known if ELREXFIO is safe and effective in children.
Sign up to stay informed about important updates for ELREXFIO.
What to expect when beginning ELREXFIO
This guide will help you prepare for treatment after your healthcare provider has prescribed ELREXFIO.
Learn if ELREXFIO is right for you
This brochure will help you learn more about what ELREXFIO is, how it works, and the results from the clinical trial.
Making your support needs a priority. Together.
Managing day-to-day life after diagnosis can be overwhelming, but you don’t have to do it alone. Pfizer Oncology Together is a support program that treats your individual needs as a priority.
Personalized support throughout treatment with ELREXFIO
If you’ve been prescribed ELREXFIO, you can receive one-on-one support from a Pfizer Patient Access Navigator during your treatment. Whether you have questions about getting started on treatment or need help navigating your insurance coverage and what your out-of-pocket costs may be, you can turn to your Patient Access Navigator for support.
Support & financial resources
If needed, we’ll help you find financial assistance options for your prescribed ELREXFIO treatment, including a co-pay savings program for eligible, commercially insured patients. Limits, terms, and conditions apply. If you need financial assistance, we can also help identify resources if you have Medicare, another government insurance plan, or don’t have health insurance.
Co-pay assistance
Eligible,* commercially insured patients† may pay as little as $0 per treatment for ELREXFIO, regardless of income.‡ Limits, terms, and conditions apply.